Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Capital Employed (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Return on Capital Employed for 13 consecutive years, with 8.84% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed fell 743.0% year-over-year to 8.84%, compared with a TTM value of 8.84% through Dec 2025, down 743.0%, and an annual FY2025 reading of 2.04%, down 96.0% over the prior year.
  • Return on Capital Employed was 8.84% for Q4 2025 at Karyopharm Therapeutics, down from 7.77% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.34% in Q3 2022 and bottomed at 8.84% in Q4 2025.
  • Average Return on Capital Employed over 5 years is 1.82%, with a median of 0.8% recorded in 2021.
  • The sharpest move saw Return on Capital Employed soared 57bps in 2022, then crashed -743bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.48% in 2021, then crashed by -30bps to 0.62% in 2022, then dropped by -12bps to 0.7% in 2023, then crashed by -102bps to 1.41% in 2024, then crashed by -527bps to 8.84% in 2025.
  • Business Quant data shows Return on Capital Employed for KPTI at 8.84% in Q4 2025, 7.77% in Q3 2025, and 6.75% in Q2 2025.